+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 6 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the effects of three different doses of AZD8965 compared to a placebo in adults aged 40 and older with Idiopathic Pulmonary Fibrosis IPF. This Phase IIb study aims to assess how well AZD8965 works, its safety, and how well participants tolerate it. Participants include those on stable doses of approved antifibrotic therapies and those not receiving such treatments. Participants will be randomly assigned to one of four groups placebo, low dose, medium dose, or high dose of AZD8965. The study lasts 24 weeks and is conducted globally at approximately 200 sites. This is a double-blind, placebo-controlled, parallel-group study, meaning neither participants nor researchers know which treatment any participant receives during the trial. During the study, participants will have their lung function measured by changes in forced vital capacity FVC at 24 weeks, along with monitoring for safety through the recording of adverse events. Additional assessments include examining the relationship between dose and efficacy, rate of lung function decline, and pharmacokinetics of AZD8965. The total participation time is 24 weeks with safety follow-up up to 25 weeks.

Age: 40Years +All GendersPhase 2
198 locations
E

Actively Recruiting

Researchers are evaluating GB-0895 as an add-on therapy for adolescents and adults with severe asthma that remains uncontrolled despite using inhaled corticosteroids and other asthma controllers. This global, multicenter, randomized, double-blind, placebo-controlled Phase 3 study aims to assess the effectiveness and safety of GB-0895 in improving asthma outcomes. Participants will receive either GB-0895 or a placebo through subcutaneous injections every six months during the treatment period. The study includes a screening and run-in phase from weeks -5 to 0, a treatment phase lasting 52 weeks, and a follow-up phase lasting from week 52 to week 90. An optional open-label extension allows continued GB-0895 treatment from week 52 through week 142. During the study, participants will undergo various assessments including lung function tests, questionnaires about asthma symptoms and quality of life, and monitoring for asthma exacerbations and adverse events. Researchers will measure outcomes such as the annual rate of asthma exacerbations and changes in lung function over 52 weeks. Safety evaluations will continue throughout treatment and follow-up. The total participation duration may extend up to nearly three years if the optional extension is chosen.

Age: 12Years - 80YearsAll GendersPhase 3
158 locations
A

Actively Recruiting

Researchers are studying whether the medicine nerandomilast can help slow lung changes in people aged 40 or older who have a family history of pulmonary fibrosis. This condition causes scarring in the lungs, making breathing difficult, and early lung changes detected by scans may lead to this scarring. The study aims to find ways to prevent lung fibrosis from getting worse in those at higher risk due to family history. Participants are randomly assigned to two groups one takes nerandomilast tablets and the other takes placebo tablets that look the same but contain no medicine. They take one tablet twice daily for about 2 to 3 years. The chance of receiving nerandomilast is 3 in 5. The study includes frequent visits during the first 2 years, approximately every 3 months, then visits every 6 months in the third year, along with phone calls every 3 months during that last year. During the study, doctors regularly check lung function and perform chest scans to monitor lung changes and see if nerandomilast affects the condition. They also track participants health and any side effects. The main measure is the time until lung changes worsen over the full trial period. The total participation time is about 2 to 3 years with ongoing assessments throughout.

Age: 40Years +All GendersPhase 3
55 locations
P

Actively Recruiting

Researchers are studying adults with pulmonary hypertension associated with interstitial lung disease PH-ILD to evaluate the effects of a 24-week daily treatment using Treprostinil Palmitil Inhalation Powder TPIP compared to a placebo. This phase 3, randomized, double-blind, placebo-controlled study aims to assess how TPIP impacts exercise capacity in this group. Participants will receive either TPIP once daily, starting at 80 micrograms and increasing to a maximum tolerated dose of 1280 micrograms, or a placebo inhaled via a capsule-based dry powder inhaler. The treatment period lasts for 24 weeks, and both groups use the same type of inhalation device to maintain blinding. During the study, participants will undergo assessments including the 6-minute walk test to measure exercise capacity and blood tests to track heart-related biomarkers like NT-proBNP. Researchers will monitor clinical worsening events, adverse effects, and plasma drug levels throughout the 24-week treatment. The study is designed to provide detailed information about TPIPs impact on PH-ILD over this period.

Age: 18Years +All GendersPhase 3
186 locations
E

Actively Recruiting

Researchers are studying adults with fibrosing interstitial lung disease ILD, excluding idiopathic pulmonary fibrosis IPF, who have been diagnosed within the last three years and may be at risk of developing progressive pulmonary fibrosis PPF. The trial aims to evaluate the effects of a medicine called nerandomilast in slowing lung function decline and disease progression in this group. Participants are randomly assigned to one of two groups one takes nerandomilast tablets, and the other takes placebo tablets that look identical but contain no medicine. The study lasts up to about 2 years and 4 months, during which participants take their assigned tablets regularly and undergo scheduled assessments to monitor their lung condition. Throughout the study, participants visit the study site regularly for tests including spirometry to measure forced vital capacity FVC and diffusing capacity of the lungs for carbon monoxide DLCO. High-resolution computed tomography HRCT scans track lung changes over time. Researchers compare these results between groups to assess treatment effects, while monitoring overall health and any side effects.

Age: 18Years +All GendersPhase 3
162 locations
R

Actively Recruiting

Researchers are evaluating the overall survival of patients with stage I epithelial ovarian cancer after they have undergone comprehensive staging surgery. This phase III trial compares the outcomes of adjuvant chemotherapy versus observation alone. The study aims to determine whether adding chemotherapy after surgery improves survival in this patient group. Participants will be randomly assigned to one of two groups. One group receives adjuvant chemotherapy, which includes either a combination of paclitaxel and carboplatin or docetaxel and carboplatin, given every three weeks for three to six cycles. Switching between paclitaxel and docetaxel is allowed if adverse events occur. The other group undergoes observation without chemotherapy. During the study, participants will be monitored for overall survival up to 60 months from randomization. Researchers will also assess relapse-free survival within the same timeframe. Evaluations include follow-ups to track disease progression, side effects, and general health. The study ensures participants receive appropriate care and measures outcomes to better understand treatment benefits and risks.

Age: 20Years +FEMALEPhase 3
103 locations